What does Compass Therapeutics, Inc. do?
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular…
What is Compass Therapeutics, Inc.'s P/E and P/B ratio?
Compass Therapeutics, Inc. has a P/E ratio of -2.1 and a P/B ratio of 0.87.
What is Compass Therapeutics, Inc.'s debt-to-equity ratio?
Compass Therapeutics, Inc. has a debt-to-equity ratio of 0.06.
How much does Compass Therapeutics, Inc. owe compared with what it owns?
Compass Therapeutics, Inc. owes $0.13 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Compass Therapeutics, Inc.'s Positivity rank?
Compass Therapeutics, Inc. is ranked #979 of 6,774 companies globally and #179 of 4,000 in United States on PositoAI, with a Positivity Score of 23,422.
Does Compass Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Compass Therapeutics, Inc..
Where can I read the latest news about Compass Therapeutics, Inc.?
Recent headlines about Compass Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Compass Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Compass Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.